During ischemic brain injury, YHJGs can decrease both AKT1 expression, potentially influencing the biological functions associated with the AKT1 signaling pathway, and the phosphorylation level of ERK1/2, thereby impacting the activity of the ERK1/2 signaling pathway and its related biological effects. The gene discussed is MAPK3; the disease is brain injury.